A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
Categories (click each to see list of all clinical trials associated with that category): GI (ONC), Pancreatic Cancer Center of Excellence - PCCE (ONC)
Current Status: Open
Phase: III (Cancer Control)
Principal Investigator: Klute, Kelsey
Contact Information:
Monica Davis
mondavis@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT06608927?term=NCT06608927&rank=1#participation-criteria
Summary
Primary Objective: To compare OS of quemliclustat + NP-Gem vs placebo + NP-Gem in all randomized patients.
Secondary Objectives: 1. To compare PFS of quemliclustat + NP-Gem vs placebo + NP-Gem in all randomized patients. 2. To assess additional measures of clinical activity in all randomized patients. 3. To assess the safety and tolerability of quemliclustat or placebo in combination with NP-Gem in all randomized patients.